Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer

Analysis from the CaPSURE™ registry

K. Clinton Cary, Nirmish Singla, Janet E. Cowan, Peter R. Carroll, Matthew R. Cooperberg

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose While androgen deprivation therapy can delay cancer progression and reduce tumor burden, its use can be limited by adverse side effects. We evaluated the effect of androgen deprivation therapy on mental and emotional well-being in men with nonmetastatic prostate cancer. Materials and Methods Participants were enrolled in the national CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, and treated with radical prostatectomy, external beam radiation therapy or brachytherapy with no androgen deprivation therapy (local); local with androgen deprivation therapy (combination); or primary androgen deprivation therapy. Emotional quality of life was evaluated by SF-36® social function, role emotional, vitality and mental health subscales before and up to 24 months after treatment. Subscales were assessed as continuous scores and as clinically meaningful declines of at least half a standard deviation since pretreatment. Associations between treatment and quality of life changes over time were evaluated with mixed modeling. Quality of life declines were evaluated with logistic regression. Results Among 3,068 men the combination and primary androgen deprivation therapy groups were older, single, with less education and higher clinical CAPRA (Cancer of the Prostate Risk Assessment) score risk than the local group (all values p

Original languageEnglish (US)
Pages (from-to)964-970
Number of pages7
JournalJournal of Urology
Volume191
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Androgens
Registries
Prostatic Neoplasms
Research
Quality of Life
Therapeutics
Brachytherapy
Prostatectomy
Group Psychotherapy
Tumor Burden
Mental Health
Radiotherapy
Logistic Models
Education
Neoplasms

Keywords

  • androgens
  • personal satisfaction
  • prostatic neoplasms
  • quality of life

ASJC Scopus subject areas

  • Urology

Cite this

Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer : Analysis from the CaPSURE™ registry. / Cary, K. Clinton; Singla, Nirmish; Cowan, Janet E.; Carroll, Peter R.; Cooperberg, Matthew R.

In: Journal of Urology, Vol. 191, No. 4, 2014, p. 964-970.

Research output: Contribution to journalArticle

Cary, K. Clinton ; Singla, Nirmish ; Cowan, Janet E. ; Carroll, Peter R. ; Cooperberg, Matthew R. / Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer : Analysis from the CaPSURE™ registry. In: Journal of Urology. 2014 ; Vol. 191, No. 4. pp. 964-970.
@article{a614cb77f6144443bd2accfcf3dd34dc,
title = "Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: Analysis from the CaPSURE™ registry",
abstract = "Purpose While androgen deprivation therapy can delay cancer progression and reduce tumor burden, its use can be limited by adverse side effects. We evaluated the effect of androgen deprivation therapy on mental and emotional well-being in men with nonmetastatic prostate cancer. Materials and Methods Participants were enrolled in the national CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, and treated with radical prostatectomy, external beam radiation therapy or brachytherapy with no androgen deprivation therapy (local); local with androgen deprivation therapy (combination); or primary androgen deprivation therapy. Emotional quality of life was evaluated by SF-36{\circledR} social function, role emotional, vitality and mental health subscales before and up to 24 months after treatment. Subscales were assessed as continuous scores and as clinically meaningful declines of at least half a standard deviation since pretreatment. Associations between treatment and quality of life changes over time were evaluated with mixed modeling. Quality of life declines were evaluated with logistic regression. Results Among 3,068 men the combination and primary androgen deprivation therapy groups were older, single, with less education and higher clinical CAPRA (Cancer of the Prostate Risk Assessment) score risk than the local group (all values p",
keywords = "androgens, personal satisfaction, prostatic neoplasms, quality of life",
author = "Cary, {K. Clinton} and Nirmish Singla and Cowan, {Janet E.} and Carroll, {Peter R.} and Cooperberg, {Matthew R.}",
year = "2014",
doi = "10.1016/j.juro.2013.10.098",
language = "English (US)",
volume = "191",
pages = "964--970",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer

T2 - Analysis from the CaPSURE™ registry

AU - Cary, K. Clinton

AU - Singla, Nirmish

AU - Cowan, Janet E.

AU - Carroll, Peter R.

AU - Cooperberg, Matthew R.

PY - 2014

Y1 - 2014

N2 - Purpose While androgen deprivation therapy can delay cancer progression and reduce tumor burden, its use can be limited by adverse side effects. We evaluated the effect of androgen deprivation therapy on mental and emotional well-being in men with nonmetastatic prostate cancer. Materials and Methods Participants were enrolled in the national CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, and treated with radical prostatectomy, external beam radiation therapy or brachytherapy with no androgen deprivation therapy (local); local with androgen deprivation therapy (combination); or primary androgen deprivation therapy. Emotional quality of life was evaluated by SF-36® social function, role emotional, vitality and mental health subscales before and up to 24 months after treatment. Subscales were assessed as continuous scores and as clinically meaningful declines of at least half a standard deviation since pretreatment. Associations between treatment and quality of life changes over time were evaluated with mixed modeling. Quality of life declines were evaluated with logistic regression. Results Among 3,068 men the combination and primary androgen deprivation therapy groups were older, single, with less education and higher clinical CAPRA (Cancer of the Prostate Risk Assessment) score risk than the local group (all values p

AB - Purpose While androgen deprivation therapy can delay cancer progression and reduce tumor burden, its use can be limited by adverse side effects. We evaluated the effect of androgen deprivation therapy on mental and emotional well-being in men with nonmetastatic prostate cancer. Materials and Methods Participants were enrolled in the national CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, and treated with radical prostatectomy, external beam radiation therapy or brachytherapy with no androgen deprivation therapy (local); local with androgen deprivation therapy (combination); or primary androgen deprivation therapy. Emotional quality of life was evaluated by SF-36® social function, role emotional, vitality and mental health subscales before and up to 24 months after treatment. Subscales were assessed as continuous scores and as clinically meaningful declines of at least half a standard deviation since pretreatment. Associations between treatment and quality of life changes over time were evaluated with mixed modeling. Quality of life declines were evaluated with logistic regression. Results Among 3,068 men the combination and primary androgen deprivation therapy groups were older, single, with less education and higher clinical CAPRA (Cancer of the Prostate Risk Assessment) score risk than the local group (all values p

KW - androgens

KW - personal satisfaction

KW - prostatic neoplasms

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84898436675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898436675&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.10.098

DO - 10.1016/j.juro.2013.10.098

M3 - Article

VL - 191

SP - 964

EP - 970

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -